2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Polo-like Kinase (PLK)

Related Products

PDF 0.57 MB

Polo-like Kinases (PLKs) are a group of highly conserved serine/threonine protein kinases that play a key role in processes such as cell division and checkpoint regulation of mitosis. In mammals, five PLKs (PLK 1-5) encompass diverse roles in centrosome dynamics, spindle formation, intra S-phase and G2/M checkpoints, and DNA damage response.

PLKs are characterized by their Polo-box domain, which mediates protein interactions. They are additionally controlled by phosphorylation, proteolysis, and transcription, depending on the biological context. PLKs are now recognized to link cell division to developmental processes and to function in differentiated cells.

Polo-like Kinase (PLK) Isoform Specific Products:

Polo-like Kinase (PLK) Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-143471
    WNY0824
    		Inhibitor
    WNY0824 (PLK1/BRD4-IN-1) is an orally active dual inhibitor of PLK1 and BET protein families, with IC50 values ​​of 22, 402.5, 150.7, 103.9, and 311.9 nmol/L for PLK1, BRD2, BRD3, BRD4, and BRDT, respectively. WNY0824 induces cell cycle arrest and apoptosis by inhibiting AR- and MYC-mediated transcriptional processes. In addition, WNY0824 also inhibits tumor growth in Enzalutamide (HY-70002) resistant CRPC xenograft tumor models.
    WNY0824
  • HY-RS10718
    Plk3 Mouse Pre-designed siRNA Set A
    		Inhibitor

    Plk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Plk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk3 Mouse Pre-designed siRNA Set A
    Plk3 Mouse Pre-designed siRNA Set A
  • HY-RS10713
    Plk1 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk1 Rat Pre-designed siRNA Set A
    Plk1 Rat Pre-designed siRNA Set A
  • HY-RS10722
    Plk4 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk4 Rat Pre-designed siRNA Set A
    Plk4 Rat Pre-designed siRNA Set A
  • HY-164955
    TTK/PLK1-IN-1
    		Inhibitor
    TTK/PLK1-IN-1 (Formula I) is the inhibitor for threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC50 of 7 nM and 72 nM. TTK/PLK1-IN-1 regulates spindle assembly checkpoint (SAC), and exhibits antitumor efficacy against TNBC.
    TTK/PLK1-IN-1
  • HY-120279A
    CFI-400437
    		Inhibitor
    CFI-400437 is an indolinone-derived, ATP-competitive kinase inhibitor with high selectivity for PLK4 (IC50 of 0.6 nM).
    CFI-400437
  • HY-115589
    YLT-11
    		Inhibitor
    YLT-11 is a potent, selective and orally active PLK4 inhibitor with Kd values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis.html" class="link-product" target="_blank">Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity.
    YLT-11
  • HY-134775A
    PLK4-IN-3
    		Inhibitor
    PLK4-IN-3 is a less active absolute stereochemistry of PLK4-IN-1. PLK4-IN-1 is a PLK4 inhibitor, with an IC50 of 0.65 μM.
    PLK4-IN-3
  • HY-149912
    CZS-241
    		Inhibitor
    CZS-241 is an orally active and selective inhibitor of Polo-like Kinase (PLK) 4 (IC50=2.6 nM). CZS-241 inhibits TRKA with an IC50 value of 2.74 μM. CZS-241 induces apoptosis and arrests cell cycle at S/G2 phase. CZS-241 shows highly potent antiproliferative activity against leukemia cell lines, and exhibits safety against normal cell lines.
    CZS-241
  • HY-148974
    PLK1-IN-5
    		Inhibitor
    PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. PLK1-IN-5 shows anticancer effects (WO2008113711A1; compound I-4).
    PLK1-IN-5
  • HY-146792
    PLK1-IN-4
    		Inhibitor
    PLK1-IN-4 is a potent and selective PLK1 inhibitor with IC50 < 0.508 nM. PLK1-IN-4 has broad antiproliferative activity against a variety of cancer cell lines. PLK1-IN-4 induces mitotic arrest at the G2/M phase checkpoint, leading to cancer cell apoptosis. PLK1-IN-4 can be used for researching hepatocellular carcinoma.
    PLK1-IN-4
  • HY-139652
    PLK1-IN-2
    		Inhibitor
    PLK1-IN-2 is a PLK1 kinase inhibitor with an IC50 value of 0.384 μM.
    PLK1-IN-2
  • HY-RS10714
    PLK2 Human Pre-designed siRNA Set A
    		Inhibitor

    PLK2 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PLK2 Human Pre-designed siRNA Set A
    PLK2 Human Pre-designed siRNA Set A
  • HY-RS10716
    Plk2 Rat Pre-designed siRNA Set A
    		Inhibitor

    Plk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Plk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Plk2 Rat Pre-designed siRNA Set A
    Plk2 Rat Pre-designed siRNA Set A
  • HY-161521
    PLK1-IN-10
    		Inhibitor
    PLK1-IN-10 (Compound 4Bb) is an orally active PLK1 PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death.
    PLK1-IN-10
  • HY-RS10717
    PLK3 Human Pre-designed siRNA Set A
    		Inhibitor

    PLK3 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PLK3 Human Pre-designed siRNA Set A
    PLK3 Human Pre-designed siRNA Set A
  • HY-15160C
    TAK-960 monohydrochloride
    		Inhibitor
    TAK-960 monohydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 monohydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 monohydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.
    TAK-960 monohydrochloride
  • HY-161046
    PLK1-IN-8
    		Inhibitor
    PLK1-IN-8 (compound TE6) is a PLK1 inhibitor, and inhibits cell proliferation by blocking the cell cycle at G2 phase. PLK1-IN-8 shows anticancer activity in vivo.
    PLK1-IN-8
  • HY-RS10711
    PLK1 Human Pre-designed siRNA Set A
    		Inhibitor

    PLK1 Human Pre-designed siRNA Set A contains three designed siRNAs for PLK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
    PLK1 Human Pre-designed siRNA Set A
    PLK1 Human Pre-designed siRNA Set A
  • HY-156336
    PLK1-IN-7
    		Inhibitor
    PLK1-IN-7 (compound 30e) is a potent PLK1 inhibitor, with an IC50 of 0.66 nM. PLK1-IN-7 exhibits antiproliferative and antitumor activities.
    PLK1-IN-7
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Polo-like Kinase (PLK) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.